Circulating free plasma tumor DNA in patients with advanced gastric cancer receiving systemic chemotherapy.

Sávia Raquel Costa NormandoPamela de Oliveira DelgadoAna Katherine Soares Barbosa RodriguesWaldec Jorge David FilhoFernando Luiz Affonso FonsecaFelipe José Silva Melo CruzAuro Del Giglio

Published in: BMC clinical pathology (2018)

At 3 months after the beginning of chemotherapy, the tDNA levels are correlated with DFS in patients with advanced gastric cancer who receive systemic chemotherapy. tDNA may be a specific, non-invasive and cost effective new biomarker for these patients.

Keyphrases

locally advanced
neoadjuvant chemotherapy
end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
squamous cell carcinoma
prognostic factors
rectal cancer
radiation therapy
circulating tumor
chemotherapy induced
patient reported outcomes
drug induced
circulating tumor cells
nucleic acid